Retrospective · public company · every claim independently verifiable. A diligence read of knowable, cited facts — not a forecast of outcomes.
A retrospective, high-level read on a public company — assembled the way every Vantage evaluation is: from primary public records, with each claim cited to its source. The numeric composite and per-domain confidence bands live in the full report; the qualitative read is below.
Guardant Health presents as a commercial-stage liquid-biopsy diagnostics company. Its core offering is comprehensive genomic profiling of advanced solid tumors from a routine blood draw — a non-invasive alternative to a tissue biopsy — and it has additionally brought a blood-based colorectal cancer screening test through to FDA approval. It is a publicly traded company (NASDAQ: GH), so its regulatory and financial record is on the public record and independently checkable. The specific clearance and approval numbers and dates are reserved for the full report.
A disciplined diligence read is not a cheerleader. Even on a company with an approved screening test, the risks that genuinely exist are worth naming: reimbursement and payer-coverage dependence, a competitive liquid-biopsy field, and screening-test adoption and performance scrutiny. Those are covered in Chapter 3 as risk considerations — qualitatively, and without invented numbers.
Every Vantage evaluation scores eight domains. This teaser shows a high-level qualitative read per domain — Strong, Moderate, or Watch — with one grounded, publicly checkable sentence each. Regulatory, Clinical, and Competitive are shown a little more fully; the rest are locked more tightly. Scores, citations, and confidence bands are in the full report.
The point of a diligence read is that it flags real risks even on a strong company. These are stated qualitatively, from the knowable public picture — no invented numbers, no forecast of outcomes.
Diagnostics revenue turns on payer coverage and coding. Dependence on reimbursement decisions is a genuine consideration a diligence read surfaces for any testing company, independent of how coverage ultimately settles.
Blood-based cancer testing is an area many well-capitalized players pursue. Competitive intensity in the liquid-biopsy field is a real consideration for any platform addressing the same clinical need.
A new blood-based screen faces both adoption friction and close scrutiny of real-world performance. Adoption pace and performance scrutiny are standard, material considerations a diligence read names explicitly rather than assumes away.
This is an abbreviated sample. A full Vantage evaluation includes every cited source, per-domain confidence bands, cohort comparables, and the remediation read. Run one on a deal you're evaluating.